NCT07264088Not yet recruiting
Identifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer
The FOLLOW UP Study - a Natural Experiment Estimating the Clinical and Cost-effectiveness of Follow up Strategies After Curative Treatment for Prostate Cancer
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
Over 20,000 patients a year in the UK get surgery or radiotherapy to cure their prostate cancer. These men then undergo regular check-ups to manage potential side effects and see if cancer recurs so it can be treated quickly. The organisation of these check-ups varies across the country as it is not known which approach is best. The four different established approaches are (i) check-ups performed in hospital outpatients by the same team that provided treatment; (ii) patients seen regularly by their GP with hospital referral as necessary; (iii) planned shared care between general practice and hospital follow up; or (iv) patients supported to provide checks on themselves (self-care) and reaching out to a doctor or a nurse when required. This study will compare these options to establish which is best for patients and makes the best use of the NHS resources.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100000 (estimated)
- First submitted
- 30 Sept 2025
- Start date
- Dec 2026
- Primary completion date
- Jul 2027
- Lead sponsor
- Imperial College London
- Diseases
- Prostate cancer
- NCT number
- NCT07264088
What you commit to
- Study type: Observational
- Planned participants: 100000
- From Dec 2026 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Men who are treated for metastatic cancer; or receiving palliative prostate cancer care;
Other
- Men who have opted out of their data being used as part of national routine data sets will be excluded (https://digital.nhs.uk/services/national-data-opt-out).
- Recruitment to the survey component of the study will be limited to a sub-cohort of eligible participants that additionally meet the following criteria:
- Alive;
- Have achieved between three to four and a half years of follow up (from completion of initial curative treatment) during the survey period.
Who the study is looking for
- All hospitals in England that provide radical prostatectomy or radical radiotherapy or focal therapy for prostate cancer and are identified by clinicians as receiving one of the four follow up strategies of interest will be eligible for inclusion in the study.
- Individual patients satisfying the following criteria will be eligible for inclusion:
- Having newly-diagnosed non-metastatic, clinically localised prostate cancer (ICD-10 code C61) in the Cancer Registry between 1 January 2018 and 31 December 2023;
- Age 18 or over at diagnosis;
- Completed primary curative treatment at an eligible hospital between 1 January 2019 and 31 December 2023 with either: radical radiotherapy +/- hormones, or radical prostatectomy with curative intent +/- lymphadenectomy, or focal therapy, in keeping with local practice;
- Alive with no disease progression or metastasis 6 months after the date of completion of primary curative treatment.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| London School of Hygiene & Tropical Medicine Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.